AstraZeneca COVID-19 vaccine shows promise in elderly, trial results by Christmas

South Australia is now in its second day of lockdown

READ MORESouth Australia enters second day of lockdown as Victoria closes its borders

Earlier this month, Australian manufacturer CSL kicked off production of 30 million doses of the Oxford-AstraZeneca vaccine, despite it still undergoing clinical trials.

Now, researchers have released preliminary results that show the vaccine produces an immune response, although it's too early to say whether it can prevent disease.

However, the researchers said they still expect CoronaVac to protect against Covid-19, citing their experience with other vaccines and evidence gathered from testing it on monkeys. "As a result, it is crucial that Covid-19 vaccines are tested in this group who are also a priority group for immunisation".

The ministry had said that the trials of COVID-19 vaccines have entered into its third phase on the global level and all countries started advance booking for the vaccines expected to be introduced in the first and second quarters of 2021. It is also generating a good antibody response.

Pyrénées : Un agent espagnol entendu pour l’empoisonnement de l’ours Cachou
Des doutes sur les circonstances de sa mort C'est ce que laisse entendre l' association pyrénéenne Pays de l'ours - Adet . Une enquête avait alors été ouverte côté espagnol avec une autopsie diligentée à Barcelone.

"We believe that this makes the vaccine suitable for emergency use during the pandemic", Zhu added.

Larger studies are now underway to evaluate immunogenicity, safety and efficacy in older adults with a wider range of comorbidities. "We hope that this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure".

In phase 1, the 144 participants were divided into two vaccination groups during screening - the days 0 and 14 vaccination cohort and the days 0 and 28 vaccination cohort.

"Our new study answers some questions about protecting older adults, but questions remain about effectiveness and length of protection, and we need to confirm our results in older adults with underlying conditions to ensure that our vaccine protects those most at risk of severe COVID-19 disease", Gilbert explained.

As pandemic surges, CDC recommends against Thanksgiving travel
The travel advice is a "strong recommendation", not a requirement, CDC official Henry Walke said on a call with reporters. "Postponing travel and staying home is the best way to protect yourself and others this year", the new guidelines state.

The results follow news this month from Pfizer Inc and BioNTech and from Moderna, as well as from Russian Federation, of experimental vaccines proving more than 90% effective, based on interim data from large, late-stage trials.

"The robust antibody and T-cell responses seen in older people in our study are encouraging". He told the British Broadcasting Corporation (BBC) on Thursday that he was "delighted" that early results show a strong immune response "even in those over 70 years of age".

No serious adverse health events related to the vaccine were seen in the participants and older people were found to have fewer side effects (such as fatigue and muscle ache) than younger participants.

Professor Pollard said: "We're still waiting to get to the point where we can do the analysis to just work out how well the vaccine can protect people, and we're getting ever closer to that".

Sia's new movie slammed for not hiring autistic actor
Sia defended herself by saying she "made the executive decision that we would do our best to lovingly represent the community". Sia was antagonistic when responding to criticism from people within the disabled community.

Latest News